<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03721562</url>
  </required_header>
  <id_info>
    <org_study_id>ARGO</org_study_id>
    <nct_id>NCT03721562</nct_id>
  </id_info>
  <brief_title>Antibiotic Resistance in Global Pediatric Oncology Centers</brief_title>
  <official_title>Antibiotic Resistance in Global Pediatric Oncology Centers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tarleton State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antibiotic resistance is one of the major health threats facing global as well as domestic&#xD;
      populations, however it is not well characterized in pediatric patients. Pediatric patients&#xD;
      receiving cancer-directed therapy have several risk factors implicated in development of&#xD;
      antibiotic resistance including multiple courses of antibiotics, repeated exposures to the&#xD;
      hospital environment, indwelling devices and chemotherapy-related damage to mucosal barriers.&#xD;
      The investigators propose to capitalize upon the unique position of St. Jude Global within&#xD;
      the global pediatric oncology community by using its regional alliance network to describe&#xD;
      the molecular epidemiology of antibiotic resistance in Gram-negative bacteria in this&#xD;
      population.&#xD;
&#xD;
      Primary Objectives&#xD;
&#xD;
        1. Describe the epidemiology and the phenotypic and previously determined molecular&#xD;
           determinants of antimicrobial resistance in Gram-negative organisms isolated from&#xD;
           pediatric diagnostic specimens in selected Central American and US sites with capacity&#xD;
           to treat pediatric cancer&#xD;
&#xD;
        2. Utilize strain typing by whole genome sequencing to describe relatedness between&#xD;
           organisms at participating sites&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participating clinical microbiology laboratories will flag any Gram-negative bacteria meeting&#xD;
      inclusion criteria. Bacteria will be subcultured; one sample will be lysed and shipped to St.&#xD;
      Jude; the remaining sample will be stored onsite for the duration of the study. Samples of&#xD;
      bacteria from both oncology and non-oncology patients will be included. Whole genome&#xD;
      sequencing will be performed on the bacterial samples at St. Jude and the genotypic and&#xD;
      phenotypic antimicrobial resistance testing (AST) results compared. Genotypic results will&#xD;
      additionally be used to describe phylogenetic relationships and potential transmission events&#xD;
      both within and between sites.&#xD;
&#xD;
      Each participating location will collect limited clinical data corresponding to disease and&#xD;
      treatment related factors on the affected patient. This will include sociodemographic&#xD;
      variables, oncologic diagnosis, treatment phase, presence of a central venous catheter or&#xD;
      other foreign body, antibiotic treatment within the past month, and previous history of&#xD;
      colonization or infection by a resistant organism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 26, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Number of isolated organisms by anatomic site and geographic site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Number of antibiotic resistance genes/mutations of interest by geographic site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patterns of organism and resistance in participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Correlation of known mutations/genes of interest with drug resistance phenotype</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic relatedness between bacteria at participating sites</measure>
    <time_frame>approximately 6 months after completion of data collection</time_frame>
    <description>Whole genome sequencing results will be used to describe whether isolated organisms appear to be related phylogenetically.</description>
  </primary_outcome>
  <enrollment type="Actual">560</enrollment>
  <condition>Antibiotic Resistant Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric (0-18 years of age) patients having a bacteria isolated from a sterile site&#xD;
        (blood, cerebrospinal fluid, body fluid) or urine positive for a Gram-negative bacteria&#xD;
        nonsusceptible to at least 1 of the following: third generation cephalosporin, fourth&#xD;
        generation cephalosporin or carbapenem OR screening positive for carbapenemase or extended&#xD;
        spectrum beta lactamase (ESBL) production.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric (0-18 years of age) patients having a bacteria isolated from a sterile site&#xD;
             (blood, cerebrospinal fluid, body fluid) or urine positive for a Gram-negative&#xD;
             bacteria nonsusceptible to at least 1 of the following: third generation&#xD;
             cephalosporin, fourth generation cephalosporin or carbapenem OR screening positive for&#xD;
             carbapenemase or extended spectrum beta lactamase (ESBL) production.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Repeated isolation of the same organism from the same patient within the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheena Mukkada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional de Niños Benjamín Bloom</name>
      <address>
        <city>San Salvador</city>
        <country>El Salvador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Nacional de Oncología Pediátrica</name>
      <address>
        <city>Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño</name>
      <address>
        <city>Panamá</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>El Salvador</country>
    <country>Guatemala</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2018</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibiotic Resistance</keyword>
  <keyword>Gram Negative Bacteria</keyword>
  <keyword>Pediatric Patients</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

